Core Insights - The Ruijin Hainan Hospital has successfully implemented 186 licensed medical device projects, 2 special medical foods, and 5 biomedical new technologies by the end of September this year, benefiting over 26,800 patients [1] - The unique drug Vusonatide, which treats achondroplasia, completed its first treatment in China at this hospital less than a year after its launch in the EU [1] - The hospital aims to leverage its public hospital platform to enhance the regional medical ecosystem and promote high-quality development of the healthcare industry in Hainan Free Trade Port, with a goal to serve nationwide and radiate to Southeast Asia [1] Group 1 - The hospital's achievements in licensed medical projects demonstrate its capability in addressing the availability of innovative medical solutions [1] - The real-world research conducted by the hospital accelerates the process of effective and widespread use of international innovative drugs and devices in China [1] - The establishment of the national regional medical center aims to enhance healthcare services and innovation in the region [1]